Aileron Therapeutics

65 articles with Aileron Therapeutics

• Aileron Therapeutics to Participate in Fireside Chat at the William Blair Biotech Focus Conference 2021

  7/8/2021

  Aileron Therapeutics announced today that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, is scheduled to participate in a fireside chat at the William Blair Biotech Focus Conference 2021 at 3:00 p.m. ET on Thursday, July 15, 2021.

• Aileron Therapeutics Announces Initiation of Randomized, Double-Blind, Placebo-Controlled Trial of ALRN-6924 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

  7/1/2021

  Aileron Therapeutics, Inc. (Nasdaq: ALRN) today announced that it has initiated  a randomized, double-blind, placebo-controlled clinical trial in the US and in Europe of ALRN-6924 as a chemoprotective agent to treat patients with non-small cell lung cancer (NSCLC) undergoing chemotherapy

• Aileron Therapeutics to be Added to the Russell Microcap® Index

  6/24/2021

  Aileron Therapeutics, a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients, announced that it is set to join the Russell Microcap® Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the U.S. market opens on June 28, 2021.

• Aileron Therapeutics to Host KOL Virtual Investor Event Discussing Opportunity for New Paradigm to Protect Cancer Patients from Chemotherapy-Induced Toxicities

  5/19/2021

  -- Fireside chat, moderated by Soumit Roy, Ph.D. of JonesTrading, will be held on  Wednesday, May 26, 2021 at 11:00 am ET -- -- Featured speakers will include hematologist Alan List, M.D. and  geriatric oncologist Lodovico Balducci, M.D. --

• Aileron Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update

  5/11/2021

  Aileron Therapeutics (NASDAQ:ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients, today reported business highlights and financial results for the first quarter ended March 31, 2021.

• Aileron Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Highlights

  3/24/2021

  2020 marked a year of successful evolution to a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients -- Advancing selective chemoprotection via p53 biomarker strategy; 50% of all cancer patients across multiple tumor types have a p53 mutation Achieved clinical proof-of-concept in Phase 1b study of ALRN-6924 in p53-mutated small cell lung cancer (SCLC)

• Aileron Therapeutics to Present at 2021 H.C. Wainwright Global Life Sciences Conference

  3/4/2021

  Aileron Therapeutics (NASDAQ:ALRN) today announced that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, will give a corporate presentation at the 2021 H.C. Wainwright Global Life Sciences Conference, which is taking place March 9 – 10, 2021.

• Aileron Therapeutics Announces Enrollment Expansion for Upcoming Phase 1b Clinical Trial of ALRN-6924 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

  3/2/2021

  Placebo-controlled trial anticipated to enroll 60 patients with advanced p53-mutated NSCLC undergoing treatment with first-line carboplatin plus pemetrexed

• Aileron Therapeutics Announces Completion of $35.9 Million Registered Direct Offering with Participation by New Fundamental Healthcare Investors Acorn Bioventures, BVF Partners, L.P. and Maven Investment Partners

  1/11/2021

  Aileron Therapeutics, Inc. (Nasdaq: ALRN) today announced the completion of its previously announced registered direct offering of 32,630,983 of its shares of common stock at a purchase price of $1.10 per share, for gross proceeds of $35.9 million, before deducting placement agent fees and other offering expenses payable by Aileron.

• Aileron Therapeutics Announces $35.9 Million Registered Direct Offering

  1/6/2021

  Aileron Therapeutics, Inc. (Nasdaq: ALRN), today announced that it has entered into definitive agreements with fundamental healthcare investors for the purchase and sale of 32,630,983 of its shares of common stock at a purchase price of $1.10 per share in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about January 8, 2021, subject to the satisfaction of customary c

• Aileron Therapeutics Provides Business Update and Outlines 2021 Strategic Priorities

  12/21/2020

  Aileron’s 2021 strategic priorities aim to advance its vision to bring chemoprotection to all patients with p53-mutant cancers regardless of cancer indication or chemotherapy. Key anticipated milestones include:    -- Initiate Phase 1b randomized, placebo-controlled clinical trial of novel chemoprotective agent ALRN-6924 in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line carboplatin doublet chemotherapy in second quarter 2021

• Aileron Therapeutics Reports Third Quarter 2020 Financial Results and Business Highlights

  11/13/2020

  Presented positive clinical proof-of-concept data from ongoing ALRN-6924 Phase 1b trial in patients with p53-mutated small cell lung cancer (SCLC) treated with topotecan in late-breaking presentation at 2020 EORTC-NCI-AACR Annual Symposium Phase 1b randomized, controlled trial in patients with p53-mutated advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy projected to start in the second quarter of 2021

• Aileron Therapeutics Announces Proof-of-Concept Clinical Data from Ongoing ALRN-6924 Phase 1b Trial Presented in Late-Breaking Presentation at the EORTC-NCI-AACR Annual Symposium

  10/24/2020

  Aileron Therapeutics announced new positive clinical data from its ongoing Phase 1b trial demonstrating clinical proof of concept that treatment with ALRN-6924 prior to second-line topotecan administration resulted in a protective effect against severe anemia, thrombocytopenia and neutropenia in patients with p53-mutated small cell lung cancer.

• Aileron Therapeutics to Host Conference Call to Discuss Results from Phase 1b Proof-of-Concept Study of Chemoprotective Therapy ALRN-6924 Being Presented at EORTC-NCI-AACR Annual Symposium

  10/20/2020

  Aileron Therapeutics (Nasdaq: ALRN) today announced that it will host a conference call and live webcast to discuss results from a Phase 1b proof-of-concept study of ALRN-6924 on Monday, October 26, 2020 at 8:30 a.m. ET

• Aileron Therapeutics Announces Proof-of-Concept Data for ALRN-6924 to be Featured in Late-Breaking Presentation at EORTC-NCI-AACR Annual Symposium

  10/12/2020

  Aileron Therapeutics announced that proof-of-concept data from the company’s Phase 1b study of ALRN-6924 will be featured in a late-breaking poster presentation during the 32nd EORTC-NCI-AACR Annual Symposium on Molecular Targets and Cancer Therapeutics, being held virtually October 24 – 25, 2020.

• Aileron Therapeutics Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital

  9/21/2020

  Aileron Therapeutics, Inc. (NASDAQ: ALRN), today announced it has entered into a common stock purchase agreement (“Purchase Agreement”) for up to $15 million with Lincoln Park Capital Fund, LLC (“LPC”), a Chicago-based institutional investor and current shareholder. In connection with the execution of the purchase agreement, LPC made an initial purchase of $500,000 of common stock at $1.36 per share. Thereafter, Aileron will have the optio

• Aileron Therapeutics to Present at Upcoming H.C. Wainwright Virtual Global Investment Conference

  9/10/2020

  Aileron Therapeutics (NASDAQ:ALRN) today announced that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, will give a corporate presentation at the upcoming H.C. Wainwright Virtual Global Investment Conference, including an update on the company’s efforts to advance chemoprotection for patients with p53-mutated cancers regardless of cancer type or chemotherapeutic drug. The presentation is scheduled for September 14, 2020

• Aileron Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update

  8/5/2020

  Aileron Therapeutics (NASDAQ:ALRN) today reported business highlights and financial results for the second quarter ended June 30, 2020.

• Aileron Therapeutics to Present at Two Upcoming Investor Conferences in August

  8/3/2020

  Aileron Therapeutics (NASDAQ:ALRN) today announced that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, will participate in two upcoming investor conferences this month. Thursday, August 6, 2020 Event: William Blair Biotech Focus Conference 2020 Time:  12:00 pm ET *Fireside chat Thursday, August 13, 2020 Event: Canaccord Genuity 40 th Annual Growth Conference Time:  4:30 pm ET *Company overview and business

• Aileron Therapeutics Announces Completion of Enrollment in Dose Optimization Expansion Cohort of Proof-of-Concept Phase 1b Study of ALRN-6924

  8/3/2020

  Study is evaluating ALRN-6924 to protect against chemotherapy-induced bone marrow toxicities in patients with p53-mutated small cell lung cancer (SCLC) treated with topotecan Previously reported positive interim data from dose optimization part of study demonstrated 0.3 mg/kg dose of ALRN-6924, now being evaluated in expansion cohort, resulted in most robust chemoprotective effects